J 2022

Autoimmunity, cancer and COVID‑19 abnormally activate wound healing pathways: critical role of inflammation

GÁL, Peter, Jan BRÁBEK, Michal HOLUB, Milan JAKOUBEK, Aleksi ŠEDO et. al.

Basic information

Original name

Autoimmunity, cancer and COVID‑19 abnormally activate wound healing pathways: critical role of inflammation

Authors

GÁL, Peter (203 Czech Republic), Jan BRÁBEK (203 Czech Republic), Michal HOLUB (203 Czech Republic), Milan JAKOUBEK (203 Czech Republic), Aleksi ŠEDO (203 Czech Republic), Lukáš LACINA (203 Czech Republic), Karolina STRNADOVÁ (203 Czech Republic), Petr DUBOVÝ (203 Czech Republic, guarantor, belonging to the institution), Helena HORNYCHOVÁ (203 Czech Republic), Aleš RYŠKA (203 Czech Republic) and Karel SMETANA JR. (203 Czech Republic)

Edition

Histochemistry and Cell Biology, NEW YORK, SPRINGER, 2022, 0948-6143

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10601 Cell biology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.300

RIV identification code

RIV/00216224:14110/22:00127917

Organization unit

Faculty of Medicine

UT WoS

000828939900001

Keywords in English

Wound healing; Granulation tissue; Peripheral nerve injury; Rheumatoid arthritis; Cancer stroma; SARSCoV- 2; Myofibroblast; IL-6; Inflammation

Tags

Tags

International impact, Reviewed
Změněno: 23/1/2023 10:32, Mgr. Tereza Miškechová

Abstract

V originále

Recent evidence indicates that targeting IL-6 provides broad therapeutic approaches to several diseases. In patients with cancer, autoimmune diseases, severe respiratory infections [e.g. coronavirus disease 2019 (COVID-19)] and wound healing, IL-6 plays a critical role in modulating the systemic and local microenvironment. Elevated serum levels of IL-6 interfere with the systemic immune response and are associated with disease progression and prognosis. As already noted, monoclonal antibodies blocking either IL-6 or binding of IL-6 to receptors have been used/tested successfully in the treatment of rheumatoid arthritis, many cancer types, and COVID-19. Therefore, in the present review, we compare the impact of IL-6 and anti-IL-6 therapy to demonstrate common (pathological) features of the studied diseases such as formation of granulation tissue with the presence of myofibroblasts and deposition of new extracellular matrix. We also discuss abnormal activation of other wound-healing-related pathways that have been implicated in autoimmune disorders, cancer or COVID-19.